Cure My Disease

Don't miss your cure!

 Log in / Sign up

Nurse coaching may help heart failure patients avoid hospital visits by mastering fluid control

NCT ID NCT07686536

Disease control Sponsor: The Third Xiangya Hospital of Central South University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This trial tests a nurse-led program designed to help people with chronic heart failure better manage fluid buildup—a common cause of hospital readmission. The program includes education, emotional support, and practical skills like daily weighing and salt restriction. Researchers will compare this approach to standard care in 88 adults with heart failure, measuring self-care, quality of life, and hospital visits over three months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
nurse-led behavioral intervention based on the Common-Sense Model of Self-Regulation
What this could lead to
If effective, this program could become a standard approach to help heart failure patients manage fluid levels at home, reducing hospital readmissions and improving quality of life.
What could go wrong
This is a small, single-center trial with 88 participants, so results may not apply broadly. The intervention is complex and may not be feasible in all healthcare settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 88 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of chronic heart failure according to the diagnostic criteria of the Chinese Society of Cardiology, with New York Heart Association (NYHA) functional class II-IV. * Aged 18 years or older. * Documented diagnosis of heart failure for at least 3 months. * Experienced documented volume overload symptoms (e.g., dyspnea, lower extremity edema) or related healthcare visits within the past 6 months. * Adequate communication, reading, and comprehension abilities. * Willing and able to provide written informed consent to participate in the study. * Assessed by the investigator as capable of adhering to the study protocol. Exclusion Criteria: * Comorbid other severe end-stage diseases (e.g., malignancy, uremia) or recent major cerebrovascular events. * History of psychiatric illness or confirmed cognitive impairment. * Comorbid other conditions that may cause fluid retention. * Lack of independent decision-making capacity. * Communication difficulties or inability to cooperate with study procedures. * Inability to use a smartphone or WeChat application. * Patients or family members with poor compliance, or those who withdraw or are lost to follow-up.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic heart failure are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

congestive heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic heart failure

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.